ASIP.org > PISA2017.org > Speaker Biographical Information

Richard L. Schilsky, MD, FACP, FASCO, FSCT

Title: "The ASCO TAPUR Trial – A Molecularly Driven Approach to Targeted Therapy"

Summary of talk: This presentation will describe the rationale, objectives, design and endpoints of ASCO's Targeted Agent and Profiling Utilization Registry (TAPUR) study. The current status of the study will be presented and challenges in its implementation and analysis will be discussed.

Short biosketch: Dr. Schilsky is the Senior Vice President and Chief Medical Officer of the American Society of Clinical Oncology (ASCO), the world's largest professional organization representing physicians who care for people with cancer. Prior to joining ASCO, Dr. Schilsky was a faculty member at the University of Chicago from 1984-2012. He served as Director of the University of Chicago Cancer Research Center (1991-99), as Associate Dean for Clinical Research (1999-2007) and as Chief of the Section of Hematology-Oncology (2009-2012). Dr. Schilsky earned his M.D. at the University of Chicago Pritzker School of Medicine in 1975. Following a residency in Internal Medicine at the University of Texas Southwestern Medical Center and Parkland Memorial Hospital, he received training in Medical Oncology and Clinical Pharmacology at the National Cancer Institute (NCI) from 1977 to 1981.

An international expert in gastrointestinal malignancies and cancer pharmacology, Dr. Schilsky has published more than 325 scientific articles, reviews and commentaries. He presently serves as a member of the Board of Directors of the Reagan-Udall Foundation for the FDA, as a member of the Board of Directors of Friends of Cancer Research, and as a member of the National Cancer Policy Forum of the National Academy of Medicine. Dr. Schilsky has served as a member of the Board of Directors of the American Society of Clinical Oncology (ASCO) and of the Conquer Cancer Foundation of ASCO and as ASCO President 2008-2009.